Last reviewed · How we verify
MaaT013
MaaT013 is a microbiota-based therapeutic that restores a healthy gut microbiome composition to treat immune-mediated diseases.
MaaT013 is a microbiota-based therapeutic that restores a healthy gut microbiome composition to treat immune-mediated diseases. Used for Steroid-refractory acute graft-versus-host disease (aGvHD).
At a glance
| Generic name | MaaT013 |
|---|---|
| Also known as | fecal microbiotherapy |
| Sponsor | MaaT Pharma |
| Drug class | Microbiota therapeutic |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
MaaT013 is a rationally-designed, consortium-based microbiota therapeutic derived from a healthy donor's fecal microbiota. It aims to restore microbial diversity and function in patients with dysbiotic conditions, thereby modulating immune responses and reducing inflammation. The drug is designed to address immune-mediated disorders by rebalancing the patient's gut microbiota ecosystem.
Approved indications
- Steroid-refractory acute graft-versus-host disease (aGvHD)
Common side effects
- Gastrointestinal disorders (nausea, diarrhea, abdominal pain)
- Fever
- Infection
Key clinical trials
- Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (PHASE2)
- MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (PHASE3)
- Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
- Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 (NA)
- Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MaaT013 CI brief — competitive landscape report
- MaaT013 updates RSS · CI watch RSS
- MaaT Pharma portfolio CI